-
Tocilizumab Impresses in Polyarticular Juvenile ArthritisTocilizumab Impresses in Polyarticular Juvenile Arthritis
Results from the pivotal CHERISH trial are so strong the US Food and Drug Administration has already approved the drug for this indication. Medscape Medical News (Source: Medscape Today Headlines)MedWorm Sponsor Message: Have a look at The Arthritis Daily, the new arthritis portal powered by MedWorm, with all the latest news and research on arthritis updated daily.
-
Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
(Source: Inflammation)
-
RoActemra® shows long-term efficacy
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced data from two phase III studies using RoActemra in patients with rheumatoid arthritis (RA): the long-term extension (LTE) follow up of the AMBITION study demonstrated long-term efficacy of RoActemra without methotrexate (MTX); and the FUNCTION study showed the clinical benefits of the medicine, alone or in combination with MTX, when used to treat patients with early RA.(1,2) These studies are being presented at the 2013 European League Against Rheumatism (EULAR) Congress. (Source: Pharmacy Europe)
-
Ask an Expert: Gardening Advice for Aging Bodies, Part 1
Patty Cassidy, a horticultural therapist, answers readers’ questions about container gardens, tools for those with arthritis and more. (Source: NYT Health)
-
Patients with early arthritis consume less alcohol than controls, regardless of type of arthritis
(Oxford University Press) Patients who have early arthritis consume less alcohol than controls, regardless of the type of arthritis, according to a new study published online in the journal Rheumatology. In rheumatoid arthritis specifically, the inverse association between alcohol and disease was greater in men than it was in women. (Source: EurekAlert! - Social and Behavioral Science)
-
MMR Booster Shots Safe, Effective in Juvenile ArthritisMMR Booster Shots Safe, Effective in Juvenile Arthritis
Children who have juvenile idiopathic arthritis were not harmed by live attenuated measles-mumps-rubella booster vaccinations but did gain additional protective immune responses. Medscape Medical News (Source: Medscape Today Headlines)MedWorm Sponsor Message: Have a look at The Arthritis Daily, the new arthritis portal powered by MedWorm, with all the latest news and research on arthritis updated daily.
-
Nurse-Led Programs Improve Outcomes in Rheumatoid ArthritisNurse-Led Programs Improve Outcomes in Rheumatoid Arthritis
The new programs empower patients to monitor their disease activity and manage comorbidities. Medscape Medical News (Source: Medscape Today Headlines)
-
MMR Booster Safe in Kids with Arthritis (CME/CE)
(MedPage Today) -- The live attenuated booster vaccine for measles, mumps, and rubella (MMR) does not worsen disease in children with juvenile idiopathic arthritis, researchers reported. (Source: MedPage Today Pediatrics)
-
Common Childhood Vaccine Won't Worsen Juvenile Arthritis
Safety of measles-mumps-rubella booster shot had previously been called into question
Source: HealthDay
Related MedlinePlus Pages: Childhood Immunization, Juvenile Rheumatoid Arthritis (Source: MedlinePlus Health News)
-
Self-Management Of Rheumatoid Arthritis Aided By Nurse-Led Programs
Data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism demonstrate the benefits of a nurse-led programme on patient self-management and the management of rheumatoid arthritis (RA) co-morbidities. The COMEDRA study was a six-month trial involving patients with RA who attended one of the twenty participating treatment centres in France. Patients were randomly allocated to one of two arms of the trial; the evaluation of nurse-led programmes on patient self-assessment or on the management of co-morbidities... (Source: Health News from Medical News Today)
-
Diagnosis In Rheumatoid Arthritis Improved By Novel Biomarkers
Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that novel antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). Four candidate biomarkers - UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21 - were investigated; as a group they demonstrated 85% specificity for RA, and were present in both early and seronegative disease, with 36% of early RA and 24% of RF- and ACCP -negative patients testing positive. RA is a chronic autoimmune disease characterised by inflammation of the joints and tendons... (Source: Health News from Medical News Today)MedWorm Sponsor Message: Have a look at The Arthritis Daily, the new arthritis portal powered by MedWorm, with all the latest news and research on arthritis updated daily.
-
Remission In Early RA Less Likely For Overweight And Obese Patients
A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that overweight and obese patients are less likely to achieve successful remission in early rheumatoid arthritis (ERA) compared to those of normal weight. Obese and overweight ERA subjects required 2.4 times more anti-TNF therapy throughout the study than normal weight participants without achieving similar remission outcomes. RA is a chronic, inflammatory autoimmune disease affecting approximately 1 in 100 people worldwide... (Source: Health News from Medical News Today)
-
Reducing Levels Of Nerve-Growth Factor May Be Key To Developing Better Pain Treatments For Arthritis
Arthritis is a debilitating disorder affecting one in 10 Canadians, with pain caused by inflammation and damage to joints. Yet the condition is poorly managed in most patients, since adequate treatments are lacking - and the therapies that do exist to ease arthritis pain often cause serious side effects, particularly when used long-term. Any hope for developing more-effective treatments for arthritis relies on understanding the processes driving this condition... (Source: Health News from Medical News Today)
-
Triple Therapy as Good as Biologics for Rheumatoid ArthritisTriple Therapy as Good as Biologics for Rheumatoid Arthritis
A cheaper 3-drug combination is as effective as biologics for patients with active rheumatoid arthritis who don't respond to methotrexate. Medscape Medical News (Source: Medscape Today Headlines)
-
RAPID™-PsA study highlights burden of psoriatic arthritis
UCB has announced new data from the RAPIDTM-PsA study on certolizumab pegol in the treatment of moderate to severe psoriatic arthritis (PsA) at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain. (Source: Pharmacy Europe)
-
Many Rheumatoid Arthritis Patients Discontinue Medication, Risking Permanent Disability And Reduced Lifespan
Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment. Loss of efficacy was the most common reason given (35.8%), followed by safety (20.1%), physician or patient preference (27.8% and 17.9%, respectively) and access to treatment (9.0%). Rates and rationale for treatment discontinuation were similar for both tumour necrosis factor inhibitors (TNFi) and non-TNFi biologics... (Source: Health News from Medical News Today)MedWorm Sponsor Message: Have a look at The Arthritis Daily, the new arthritis portal powered by MedWorm, with all the latest news and research on arthritis updated daily.
-
Risk Of ACPA-Negative Rheumatoid Arthritis Increased By Childbirth
Epidemiological data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that pregnancy carried to childbirth (parity) increases the risk of ACPA-negative* rheumatoid arthritis (RA). The increased risk was demonstrated in women aged 18-44 who have had a child (2.1, 95% CI 1.4-3.2), but not in older women, and was more pronounced among those women with delivery during the first year of symptoms. RA is an autoimmune disease characterised by inflammation of the joints and tendons... (Source: Health News from Medical News Today)
-
In Children With SJIA, Canakinumab Allows Discontinuation Of Corticosteroids
Study findings first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA. Successful CS tapering was achieved within 20 weeks in almost half of patients (44.5%, p JIA is a chronic arthritis occurring in 1 in every 1,000 children; SJIA is a subset occurring in 10%-20% of cases, involving the body as a whole and impacting small joints such as hands, wrists, knees and ankles... (Source: Health News from Medical News Today)
-
Focus On Well-Being Could Keep Patients With Arthritis In Workforce
Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that indicators of depression are stronger predictors of work disability in early arthritis than disease activity or response to therapy... (Source: Health News from Medical News Today)
-
The Antiinflammatory and Antiarthritic Properties of Ethanol Extract of Hedera helix
Anuradha RaiIndian Journal of Pharmaceutical Sciences 2013 75(1):99-102The ethanol Hedera helix plant extract was tested for its antiinflammatory properties. Intraperitoneal injections of 7.5 ml/kg wt ethanol extract showed antiinflammatory activity with 88.89% inhibition as compared to reference drug diclofenac, which showed 94.44% inhibition in formalin-induced paw oedema. As formalin-induced paw oedema closely resembles human arthritis, the antiarthritic property of ethanol extract of Hedera helix was also investigated. The visible reduction in arthritic symptoms by extract of Hedera helix suggests the potential of the plant extract against inflammation and arthritis. (Source: Indian Journal of Pharmaceutical Sciences)MedWorm Sponsor Message: Have a look at The Arthritis Daily, the new arthritis portal powered by MedWorm, with all the latest news and research on arthritis updated daily.
|
Artritis||O bolesti 
